BioGend Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
BioGend Therapeutics has a total shareholder equity of NT$876.9M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$941.3M and NT$64.5M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | n/a |
| Cash | NT$633.87m |
| Equity | NT$876.85m |
| Total liabilities | NT$64.50m |
| Total assets | NT$941.35m |
Financial Position Analysis
Short Term Liabilities: 6733's short term assets (NT$724.9M) exceed its short term liabilities (NT$28.6M).
Long Term Liabilities: 6733's short term assets (NT$724.9M) exceed its long term liabilities (NT$35.9M).
Debt to Equity History and Analysis
Debt Level: 6733 is debt free.
Reducing Debt: 6733 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6733 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6733 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 0.8% each year